For ICC/IF: Use at a dilution of 1:100-1:1000. For WB: Use at a dilution of 1:100-1:1000. For IHC-P: Use at a dilution of 1:100-1:1000. For FACS: Use at a dilution of 1:100-1:1000 for 1x10^6 cells. For IP: Use at a concentration of 2-10μg/mg lysate. Optimal dilutions/concentrations should be determined by the researcher.
Clone GT12 binds to linear repetitive epitope in the PG region and allows for selective detection of both native and denatured CA IX without cross-reactivity to other carbonic anhydrases.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Batch dependent (Please refer to the vial label for the specific concentration.)
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Carbonic Anhydrase 9 , Caix , Mn , Ca9
Carbonic anhydrase IX (CA IX) is a member of the CA family of zinc-binding enzymes that catalyze a reversible conversion between carbon dioxide and carbonic acid, in a reaction that involves facilitated hydration of CO2 to H2CO3 followed by the spontaneous dissociation of H2CO3 into bicarbonate and proton. The CA IX molecule consists of a large extracellular domain (ECD), single-pass transmembrane region (TM) and a short intracytoplasmic (IC) tail. The ECD contains an N-terminally located PG-like region (which is absent from the other carbonic anhydrase isoforms) and a centrally located, well conserved catalytic domain (CA). CA IX is a cell surface protein that is present in human tumors, but not in the corresponding normal tissues. Moreover, expression of CA IX correlates with poor prognosis in many tumor types. CA IX plays a role in two phenomena involved in development of tumor phenotype - control of cell adhesion and pH regulation. Tight association of CA IX with tumors is to a major part related to tumor hypoxia.